Key Details
Price
$97.50Last Dividend
$3.74Annual ROE
27.97%Beta
0.19Events Calendar
Next earnings date:
Jan 31, 2025Recent quarterly earnings:
Oct 29, 2024Recent annual earnings:
Jan 31, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Mar 07, 2024Next split:
N/ARecent split:
Apr 09, 2019Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
On Thursday, MSN Pharmaceuticals took another step closer to releasing its generic version of Novartis' popular heart-failure medication, Entresto. A U.S. appeals court lifted a temporary hold on MSN's launch, allowing them to move forward.
On Thursday, Outlook Therapeutics, Inc. (OTLK) finished analyzing the full 12-week safety and effectiveness results for NORSE EIGHT, which studied ONS-5010 in patients with wet age-related macular degeneration (wet AMD).
On Wednesday, a federal judge in Washington, D.C. denied Novartis' last-minute attempt to stop MSN Pharmaceuticals from releasing a generic version of its popular heart-failure medication, Entresto.
Novartis AG (NYSE:NVS) will participate in the 43rd Annual Healthcare Conference hosted by J.P. Morgan on January 14, 2025, at 12:00 PM ET. The company's CEO, Vas Narasimhan, will be among the speakers. Richard Vosser will also be part of the conference call.
Basel, January 13, 2025 – Novartis is happy with the US Court of Appeals for the Federal Circuit's (CAFC) ruling that confirms the validity of the Entresto® (sacubitril/valsartan) combination patent.
In 2024, Novartis had a significant rise in stock prices but faced a 13% drop after their Q3 earnings report, which could be seen as a chance to buy at a lower price. Although their Q3 results were strong, worries about important drug patents expiring in 2025 led to a sell-off. However, Novartis' strong pipeline and upcoming product launches are likely to help counterbalance the impact of these patent expirations, suggesting a positive outlook for the future.
Can science succeed in the challenging environment of the Trump administration? Brian Sozzi, the executive editor of Yahoo Finance, has an in-depth conversation with Vas Narasimhan, the CEO of Novartis (NVS).
The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.
NVS' phase III trial of the experimental gene therapy called Intrathecal onasemnogene abeparvovec (OAV101IT) has achieved its main objective.
The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.
FAQ
- What is the primary business of Novartis AG?
- What is the ticker symbol for Novartis AG?
- Does Novartis AG pay dividends?
- What sector is Novartis AG in?
- What industry is Novartis AG in?
- What country is Novartis AG based in?
- When did Novartis AG go public?
- Is Novartis AG in the S&P 500?
- Is Novartis AG in the NASDAQ 100?
- Is Novartis AG in the Dow Jones?
- When was Novartis AG's last earnings report?
- When does Novartis AG report earnings?
- Should I buy Novartis AG stock now?